<u date-time="6p0nF5Fw"></u><sub date-time="ty6QgzSZ"></sub><sub date-time="w1Z5M"><small dropzone="jAOFPW"></small></sub> Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Randomized Controlled Trial
. 2020 Dec 10;383(24):2333-2344.
doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.

"VSports手机版" Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H Stone  1 , Matthew J Frigault  1 , Naomi J Serling-Boyd  1 , Ana D Fernandes  1 , Liam Harvey  1 , Andrea S Foulkes  1 , Nora K Horick  1 , Brian C Healy  1 , Ruta Shah  1 , Ana Maria Bensaci  1 , Ann E Woolley  1 , Sarah Nikiforow  1 , Nina Lin  1 , Manish Sagar  1 , Harry Schrager  1 , David S Huckins  1 , Matthew Axelrod  1 , Michael D Pincus  1 , Jorge Fleisher  1 , Chana A Sacks  1 , Michael Dougan  1 , Crystal M North  1 , Yuan-Di Halvorsen  1 , Tara K Thurber  1 , Zeina Dagher  1 , Allison Scherer  1 , Rachel S Wallwork  1 , Arthur Y Kim  1 , Sara Schoenfeld  1 , Pritha Sen  1 , Tomas G Neilan  1 , Cory A Perugino  1 , Sebastian H Unizony  1 , Deborah S Collier  1 , Mark A Matza  1 , Janeth M Yinh  1 , Kathryn A Bowman  1 , Eric Meyerowitz  1 , Amna Zafar  1 , Zsofia D Drobni  1 , Marcy B Bolster  1 , Minna Kohler  1 , Kristin M D'Silva  1 , Jonathan Dau  1 , Megan M Lockwood  1 , Caroline Cubbison  1 , Brittany N Weber  1 , Michael K Mansour  1 ; BACC Bay Tocilizumab Trial Investigators
Collaborators, Affiliations
Randomized Controlled Trial

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 (VSports注册入口)

John H Stone et al. N Engl J Med. .

V体育官网入口 - Abstract

Background: The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear. VSports手机版.

Methods: We performed a randomized, double-blind, placebo-controlled trial involving patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hyperinflammatory states, and at least two of the following signs: fever (body temperature >38°C), pulmonary infiltrates, or the need for supplemental oxygen in order to maintain an oxygen saturation greater than 92%. Patients were randomly assigned in a 2:1 ratio to receive standard care plus a single dose of either tocilizumab (8 mg per kilogram of body weight) or placebo. The primary outcome was intubation or death, assessed in a time-to-event analysis. The secondary efficacy outcomes were clinical worsening and discontinuation of supplemental oxygen among patients who had been receiving it at baseline, both assessed in time-to-event analyses V体育安卓版. .

Results: We enrolled 243 patients; 141 (58%) were men, and 102 (42%) were women. The median age was 59. 8 years (range, 21. 7 to 85. 4), and 45% of the patients were Hispanic or Latino. The hazard ratio for intubation or death in the tocilizumab group as compared with the placebo group was 0. 83 (95% confidence interval [CI], 0. 38 to 1. 81; P = 0. 64), and the hazard ratio for disease worsening was 1. 11 (95% CI, 0. 59 to 2. 10; P = 0. 73). At 14 days, 18. 0% of the patients in the tocilizumab group and 14. 9% of the patients in the placebo group had had worsening of disease. The median time to discontinuation of supplemental oxygen was 5. 0 days (95% CI, 3. 8 to 7. 6) in the tocilizumab group and 4. 9 days (95% CI, 3. 8 to 7. 8) in the placebo group (P = 0. 69). At 14 days, 24. 6% of the patients in the tocilizumab group and 21. 2% of the patients in the placebo group were still receiving supplemental oxygen V体育ios版. Patients who received tocilizumab had fewer serious infections than patients who received placebo. .

Conclusions: Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19. Some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide. (Funded by Genentech; ClinicalTrials. gov number, NCT04356937 VSports最新版本. ). .

PubMed Disclaimer

Conflict of interest statement

Dr. Stone reports receiving grant support and consulting fees from Principia Biopharma and Roche, grant support from Viela, advisory board fees and consulting fees from Sanofi, and consulting fees from Chemocentryx, Celgene, AbbVie, Chugai, Gruenthal, GlaxoSmithKline, InflaRx, INSmed, Regeneron, and Roivant; Dr VSports注册入口. Frigault, receiving consulting fees and advisory board fees from Novartis and Celgene/BMS and consulting fees from Kite/Gilead and Arcellx; Dr. Healy, receiving grant support from Analysis Group, Celgene (Bristol-Myers Squibb), Verily Life Sciences, Novartis, Merck Serono, and Genzyme; Dr. Dougan, receiving grant support from Novartis and Eli Lilly, grant support and consulting fees from Genentech, consulting fees from ORIC Pharmaceuticals, Partner Therapeutics, and Tillotts Pharma, and advisory board fees from Neoleukin Therapeutics; Dr. Kim, receiving advisory board fees from Biomarin; Dr. Neilan, receiving consulting fees from Parexel and Intrinsic Imaging, advisory board fees from AbbVie, Bristol-Myers Squibb, and H3 Biomedicine, and grant support from AstraZeneca; Dr. Unizony, receiving consulting fees from Janssen and Kiniksa and grant support from Genentech; Dr. Bolster, receiving grant support from Amgen, AbbVie, Pfizer, Cumberland, and Corbus Pharmaceuticals, advisory board fees from Gilead Sciences, consulting fees from Custom Learning Designs, honoraria from Merck Manual, and investments in Johnson & Johnson; Dr. Mansour, receiving consulting fees from Vericel, SmartPharm Therapeutics, Pulsethera, GenMark Diagnostics, Globe Life Sciences, and Day Zero Diagnostics, grant support from Thermo Fisher Scientific and Genentech, advisory board fees from Celularity, holding pending patent 14/110,443 on fungal particles, and pending patent 15/999,463 on cellular therapy for infections. No other potential conflict of interest relevant to this article was reported.

V体育2025版 - Figures

Figure 1
Figure 1. Screening, Randomization, and Outcomes.
The patient who was intubated before receiving placebo was excluded from the modified intention-to-treat population but included in the safety population.
Figure 2
Figure 2. Kaplan–Meier Analyses of Efficacy Outcomes.
Shown are Kaplan–Meier curves for the time-to-event analyses of mechanical ventilation or death (Panel A); clinical worsening, defined as an increase in score on an ordinal clinical improvement scale (scores range from 1 to 7, with higher scores indicating worse clinical condition) by at least 1 point among patients who had been receiving supplemental oxygen at baseline or at least 2 points among those who had not been receiving supplemental oxygen at baseline (Table S2) (Panel B); and discontinuation of supplemental oxygen among patients who had been receiving it at baseline (Panel C).
See this image and copyright information in PMC

"VSports app下载" Comment in

VSports注册入口 - References

    1. Centers for Disease Control. United States COVID-19 cases and deaths by state ("V体育官网入口" https://covid.cdc.gov/covid-data-tracker/).
    1. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-1720. - "VSports app下载" PMC - PubMed
    1. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med. DOI: 10.1056/NEJMcp2009249. - "VSports app下载" DOI - PubMed
    1. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:811-818. - PMC - PubMed
    1. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802-810. - PMC - PubMed

Publication types (V体育官网入口)

MeSH terms

Associated data